BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 26056179)

  • 21. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storer BE; Guthrie KA; Schoch HG; Maloney DG; Sandmaier BM; Storb R
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):105-12. PubMed ID: 25278458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.
    Warlick ED; Peffault de Latour R; Shanley R; Robin M; Bejanyan N; Xhaard A; Brunstein C; Sicre de Fontbrune F; Ustun C; Weisdorf DJ; Socie G
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):357-63. PubMed ID: 25452032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.
    Martin PS; Li S; Nikiforow S; Alyea EP; Antin JH; Armand P; Cutler CS; Ho VT; Kekre N; Koreth J; Luckey CJ; Ritz J; Soiffer RJ
    Haematologica; 2016 Apr; 101(4):499-505. PubMed ID: 26768686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning.
    Konuma T; Kato S; Ooi J; Oiwa-Monna M; Kawamata T; Tojo A; Takahashi S
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1150-5. PubMed ID: 24727335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.
    Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation.
    Yam C; Crisalli L; Luger SM; Loren AW; Hexner EO; Frey NV; Mangan JK; Gao A; Stadtmauer EA; Porter DL; Reshef R
    Am J Hematol; 2016 Sep; 91(9):883-7. PubMed ID: 27197602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning.
    Malard F; Fürst S; Loirat M; Chevallier P; El-Cheikh J; Guillaume T; Delaunay J; Le Gouill S; Moreau P; Blaise D; Mohty M
    Leukemia; 2013 Nov; 27(11):2113-7. PubMed ID: 23752174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
    Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
    Dunbar EM; Buzzeo MP; Levine JB; Schold JD; Meier-Kriesche HU; Reddy V
    Haematologica; 2008 Dec; 93(12):1852-8. PubMed ID: 18945751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
    Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
    J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.
    Crisalli LM; Hinkle JT; Walling CC; Sell M; Frey NV; Hexner EO; Loren AW; Luger SM; Stadtmauer EA; Porter DL; Reshef R
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1203-1208. PubMed ID: 29408506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
    Hwang YY; Mohty M; Chim CS
    Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.